VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have signed a strategic partnership that will establish the world’s first primate gene therapy R&D center. The center will build advanced vector screening and optimization platforms to provide unique CRO services to the rapidly growing gene and cell therapy industry. VectorBuilder brings world-leading gene delivery technologies to the venture, while Landau will provide NHP model construction expertise using Macaca fascicularis (crab-eating macaque) and Macaca mulatta (rhesus macaque) species. More specifically, the center will combine directed molecular evolution with in vivo screening in NHPs, resulting in the next generation of gene delivery vectors suitable for human clinical applications. In particular, the center will focus on improving the specificity in tissue targeting and expression pattern of vectors, as well as aiming to reduce toxicity and immunogenicity.

“Nonhuman primates share high degrees of similarities with humans in terms of anatomy, genome function, immunity and physiology. They are therefore ideal animal models for screening and optimizing gene therapy vectors,” said VectorBuilder’s Chief Scientist, Dr. Bruce Lahn. “We believe that by working closely with Landau, we will be able to build a leading CRO capable of providing these much-needed services to the gene and cell therapy community.”

Landau’s President Mr. Lei Fan added: “VectorBuilder is a global pioneer in gene delivery, and we are very pleased to be partnering with the company. The launch of this center marks a major milestone in genetic medicine, and we hope that this will enable us to join hands with other leading biopharmaceutical companies around the world to develop the next generation of gene therapy drugs.”